Regents Of The University Of California Caribou Biosciences, Inc. Transaction History

Regents Of The University Of California

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 02, 2022	SELL	$5.34 - $12.79 $484,081 - $1.16 Million	-90,652 Reduced 50.0%	90,652 $956,000
Q1 2022 Apr 25, 2022	BUY	$8.42 - $15.32 $1.53 Million - $2.78 Million	181,304 New	181,304 $1.66 Million

134

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $87M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Regents Of The University Of California, based on Form 13F filings with the SEC.

Stay updated on Regents Of The University Of California with notifications on news.